ACHC Accreditation Marks a Key Step in Preparing for the Introduction of Eve
New York, NY – June 5th, 2026 — Wandercraft has achieved Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Orthotic Fitter accreditation from the Accreditation Commission for Health Care (ACHC). This milestone reflects the company's commitment to rigorous national standards for durable medical equipment quality, compliance, and patient care.
The accreditation marks an important step in Wandercraft’s broader strategy to prepare for the widely anticipated introduction of EveTM, the company’s self-balancing personal exoskeleton designed for home use. By pursuing DMEPOS Orthotic Fitter accreditation now, Wandercraft is working to ensure that once Eve receives FDA clearance, eligible individuals will be able to obtain their device directly from the company and have it covered by their Medicare insurance.
Following FDA clearance, Eve will be available for trial and training at the Walk in New York by Wandercraft neurorehabilitation clinic.
What ACHC DMEPOS Accreditation Means
ACHC accreditation is not a checkbox. It is a rigorous, standards-driven process that evaluates an organization across quality, operational compliance, supplier qualifications, and patient rights. This framework is the same one Medicare uses to assess DMEPOS suppliers for enrollment. Achieving this recognition signals that Wandercraft operates with the systems, documentation, personnel, and quality expected by the country's largest payer.
“ACHC accreditation gives patients, clinicians, prescribers, and payers added confidence that Wandercraft is building the quality and compliance infrastructure needed to support advanced mobility technology,” said Josh Breighner, PT, DPT, Reimbursement, Access, and Policy Manager at Wandercraft. “For us, this is more than a credential. It is a foundation of trust in our standards, readiness, and commitment to helping personal exoskeleton technology move responsibly from the clinic to the home.”
A Strategic Step Toward Eve
This accreditation is one of several deliberate steps Wandercraft is taking to prepare for the commercial launch of Eve, a first-of-its-kind device intended for home use. This advanced technology solution is designed for individuals with severe mobility impairments, starting with spinal cord injuries (SCI), and is engineered to adapt to users’ movements in real time, ensuring a smooth, stable walking experience.
Bringing a device like Eve into the home isn't simply a clinical event. It requires a fully compliant supply chain, qualified personnel, documented quality systems, and a reimbursement infrastructure that meets the standards of Medicare and commercial payers.
The Vision: From Clinic to Home
Walk in New York is a model for how Wandercraft envisions the full continuum of exoskeleton care. It is a place where individuals can experience Atalante X®, an FDA-cleared rehabilitation exoskeleton used at more than 150 centers worldwide, and build upright mobility in a clinical environment. Then, when appropriate, and subject to regulatory clearance and insurance coverage, individuals can transition to Eve for personal use at home.
That pathway, from hands-on clinical training to qualified home deployment, requires the kind of accredited, compliant infrastructure that Wandercraft has now built. ACHC DMEPOS accreditation helps support the continuum of trust among patients, prescribers, clinicians, and payers as personal exoskeleton technology moves closer to home use.
For individuals living with severe mobility impairments, this is a step toward a future in which standing and walking in one’s own home is a real, accessible option. Wandercraft is deliberately and responsibly building toward that future, with the people it serves at the center of every decision.
